Antitumor Compound, Combretastatin A4 Phosphate (CA4P)
Combretastatin A4 phosphate (CA4P), a water-soluble antitumor prodrug of Combretastatin A4, is converted to Combretastatin A4 by metabolism. CA4P inhibits microtubule polymerization, thereby inducing mitotic arrest and apoptosis in endothelial cells. It has been reported that CA4P has significant effects on tumor vascularization by disrupting vascular endothelial cadherin.
References
- Antineoplastic agents. 322. Synthesis of combretastatin A-4 prodrugs
- G. R. Pettit, C. Jr. Temple, V. L. Narayanan, R. Varma, M. J. Simpson, M. R. Boyd, G. A. Rener, N. Bansal, Anti-Cancer Drug Des. 1995, 10, 299.
- Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues
- G. M. Tozer, V. E. Prise, J. Wilson, R. J. Locke, B. Vojnovic, M. R. L. Stratford, M. F. Dennis, D. J. Chaplin, Cancer Res. 1999, 59, 1626.
- Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling
- L. Vincent, P. Kermani, L. M. Young, J. Cheng, F. Zhang, K. Shido, G. Lam, H. Bompais-Vincent, Z. Zhu, D. J. Hicklin, P. Bohlen, D. J. Chaplin, C. May, S. Rafii, J. Clin. Invest. 2005, 115, 2992.

|